Microcap Ledger Cellectar Biosciences, Inc. $CLRB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Florham Park, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 9,452,108 [10-Q 2026-08-13]
What the company doesAI summary of filing
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing cancer drugs using its proprietary phospholipid drug conjugate (PDC) delivery platform. The company's lead programs include iopofosine I-131, a radioconjugate in pivotal clinical trials for relapsed/refractory Waldenstrom macroglobulinemia; CLR 125, an iodine-125 Auger-emitting radioconjugate in Phase 1b testing for triple-negative breast cancer; and CLR 225, an actinium-225 based radioconjugate in preclinical development for solid tumors. The company generates no revenue and is primarily focused on clinical development of its radioconjugate PDC programs, with additional pipeline candidates in preclinical stages using various payloads including small molecules, peptides, and oligonucleotides. [10-K 2026-03-04]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$12.58M | −$10.86M | $33.99M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | — | −$21.79M | −$23.12M | $13.20M | [DEF 14A 2026-05-28] |
| FY ended Dec 2024 | — | −$44.58M | −$47.58M | $23.29M | [DEF 14A 2026-05-28] |
- Quarterly cash burn
- −$5.43M
- Cash runway Estimate
- ~18.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-07 | 46,079,875 | [10-K 2025-03-13] |
| 2025-05-09 | 46,079,875 | [10-Q 2025-05-13] |
| 2025-08-12 | 3,192,040 | [10-Q 2025-08-14] |
| 2025-11-10 | 4,240,134 | [10-Q 2025-11-13] |
| 2026-02-24 | 4,240,129 | [10-K 2026-03-04] |
| 2026-04-29 | 4,240,129 | [10-K/A 2026-04-30] |
| 2026-05-12 | 7,991,812 | [10-Q 2026-05-14] |
| 2026-08-11 | 9,452,108 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-05-19; declared effective 2026-06-01 [S-1 2026-05-19]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-31. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-31] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-08-04 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-10 | 8-K | Director or officer change; Shareholder vote results |
| 2026-06-05 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-06-02 | 424B3 | Prospectus or prospectus supplement |
| 2026-05-29 | S-1/A | Registration statement |
Alerts for $CLRB
Email me when Cellectar Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.